Results 101 to 110 of about 1,327 (120)

The use of stereotactic ablative body radiotherapy (SABR) for oligoprogressive cancers. [PDF]

Transl Cancer Res
Bhimani J, Chadha A, Navani N, Hiley CT.
europepmc   +1 more source

Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer. [PDF]

EJNMMI Res
Trapp C, Brose SF, Keilholz M, Li M, Schmidt-Hegemann NS, Belka C, Berg E, Weinhold P, Casuscelli J, Stief C, Sheikh G, Rogowski P.   +11 more
europepmc   +1 more source

Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer. [PDF]

Cancers (Basel)
Mihailescu M, Fish AG, Madoff DC.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations

Cancers, 2022
Domenico Galetta, Antonio Rossi
exaly  

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study

European Urology, 2021
Samir Patel, Georg A. Bjarnason, Rebecca KS Wong   +2 more
exaly  

Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer

European Urology Oncology, 2021
Charlien Berghen, Piet Ost, Gert De Meerleer   +2 more
exaly  

Management of oligoprogression in non-small cell lung cancer patients

Medical Oncology, 2022
Alfredo Tartarone, Rosa Lerose
exaly